scholarly journals The Diagnostic Significance of Coapplying a Rabeprazole Test with the SF-36 for Gastroesophageal Reflux Disease

2013 ◽  
Vol 2013 ◽  
pp. 1-7 ◽  
Author(s):  
Ying Chen ◽  
Feng Wang ◽  
Yuanxi Jiang ◽  
Chen Wang ◽  
Liwen Yao ◽  
...  

Gastroesophageal reflux disease is a diversity disease that affects life quality of people in the world. Due to the complicated pathogenesis and variations in clinical manifestations, there is still no true gold standard for GERD diagnosis, and it is still difficult to diagnose this disease in some patients. The proton pump inhibitor’s diagnostic test (the PPI test) is noninvasive, of low cost, tied to treatment, and widely accepted. Our aim is to evaluate the diagnostic significance of coapplying a rabeprazole test with the SF-36 for GERD in this study. Our study shows that the SF-36 in combination with the rabeprazole test can screen GERD patients and increase the sensitivity and specificity of GERD diagnosis through reference to the change in SF-36 score before and after the treatment (65 in the trial).

2021 ◽  
Vol 5 (6) ◽  
pp. 366-372
Author(s):  
I.V. Matoshina ◽  
◽  
M.A. Livzan ◽  
M.M. Fedorin ◽  
I.V. Lapteva ◽  
...  

Aim: to evaluate the efficacy and safety of combined therapy with a proton pump inhibitor (PPI) and an esophagoprotector to relieve the symptoms of reflux esophagitis, improve the life quality of patients and achieve faster and complete disease remission. Patients and Methods: a randomized study included 60 patients, including 33 men (mean age 40.96±13.44 years) and 27 women (mean age 48.29±12.69 years) with a duration of gastroesophageal reflux disease (GERD) of 21.85±15.48 months and C/D stage of reflux esophagitis. Depending on the prescribed treatment, the patients were divided into 2 groups of 30 subjects. Patients of the main group received complex therapy: PPI pantoprazole 40 mg once per day and esophagoprotector based on hyaluronic acid, chondroitin sulfate and poloxamer 407. In the comparison group, only pantoprazole was prescribed at the same dosage. The duration of the treatment course in both groups was 4 weeks. Before and after treatment, the presence and severity of complaints were assessed on the Likert scale, life quality according to the SF-36 questionnaire and endoscopic examination data. Results: after the end of the therapy course, a statistically significant decrease in the severity of epigastric burning, regurgitation, substernal pain, gaseous eructation, odynophagia and dysphagia was found both in the main group (in all cases p<0.05, Wilcoxon Matched Pairs Test) and the comparison group (in all cases p<0,05, Wilcoxon Matched Pairs Test). The use of combination therapy made it possible to achieve a more significant improvement in the life quality of patients in all indicators versus PPI monotherapy. In addition, 3 (10%) patients of the main group achieved endoscopic remission, while there were no such patients in the comparison group. The use of esophagoprotector in addition to PPI made it possible to reach the primary and secondary endpoints significantly more commonly versus during monotherapy. Conclusion: the obtained data indicate the high efficiency and safety of PPI therapy in combination with esophagoprotector for relieving the disease symptoms and improving the life quality of patients, faster and complete remission of reflux esophagitis by additional restoration of the esophageal mucosa resistance. Esophagoprotector as a component of complex therapy together with PPI allows achieving clinical and endoscopic disease remission in patients with erosive esophagitis in shorter terms. KEYWORDS: gastroesophageal reflux disease, esophageal mucosa resistance, esophagoprotection, proton pump inhibitor, quality of life. FOR CITATION: Matoshina I.V., Livzan M.A., Fedorin M.M., Lapteva I.V. Efficacy of combined therapy in patients with erosive gastroesophageal reflux disease. Russian Medical Inquiry. 2021;5(6):366–372 (in Russ.). DOI: 10.32364/2587-6821-2021-5-6-366-372.


Author(s):  
V. P. Synelnik ◽  
N. A. Tkachenko ◽  
A. S. Suprun

This study was aimed at assessing the quality of life of 52 former fire-fighters of the Chornobyl nuclear power plant disaster with comorbidity of essential hypertension and gastroesophageal reflux disease. The subjects were divided into two groups similar by the sex and age (I group included 26 individuals with essential hypertension and II group included 26 individuals with comorbidity of essential hypertension and gastroesophageal reflux disease), their average age was 58,5±0,8 years. All patients received standard therapy (in accordance with the nosological form) added by the preparation Actovegin "Takeda Austria GmbH" in a dose of 200 mg once a day. The model, which underlies the designing of scales and total measurements of the SF-36 questionnaire, has three levels: 36 questions, 8 scales, formed by 2-10 questions; 2 total measurements, which are combined into scales. After calculating each indicator for separate scale, it was necessary to calculate the value of general indicators for the physical component and the psychological component of health taking into account the Z-value. In addition, when assessing the quality of life, three levels of assessment were conditionally identified: the minimum level ranged from 0 to 40 scores, satisfactory level – from 41 to 70 scores and the optimal ranged from 61 to 100 scores. The patients of the first group when having completed the therapy demonstrated statistically significantly improved indicators from 61.1 (0-100) scores to 71, 3 (0-100) (p ≤ 0.05) that consequently means the restrictions in role functioning due to physical condition (PF) decreased, overall health (OH) improved (scores increased from 42.7 (35-47) to 52.1 (47-60)) as well as the role functioning due to emotional state (ER) from 67.9 (0-100) to 76.5 (0-100) points. The second group when having completed the standard therapy added with Actovegin demonstrated statistically significantly improved indicators for most of the scales, and as a result, the subjective assessment of their quality of life was improved (p ≤ 0.05). Thus, the study has shown including Actovegin into standard therapy significantly improves most of the life quality parameters in both groups of the former fire-fighters of the Chornobyl nuclear power plant disaster. But, it should be noted that the indicators of pain scales and the state of overall health as parameters of life quality for the patients with comorbidy of hypertension and gastroesophageal reflux disease were fount at a minimum level compared with the patients having essential hypertension that indicates more significant restrictions in some fields of daily life activity for patients with comorbid pathology.


2017 ◽  
Vol 10 (2) ◽  
pp. 78-83 ◽  
Author(s):  
Shou-Wu Lee ◽  
Teng-Yu Lee ◽  
Han-Chung Lien ◽  
Yen-Chun Peng ◽  
Hong-Jeh Yeh ◽  
...  

2007 ◽  
Vol 44 (2) ◽  
pp. 168-177 ◽  
Author(s):  
Giedre Ingrid das Neves Pereira ◽  
Carlos Dario da Silva Costa ◽  
Luciana Geocze ◽  
Aldenis Albaneze Borim ◽  
Rozana Mesquita Ciconelli ◽  
...  

INTRODUÇÃO: Estudos têm demonstrado ser a doença do refluxo gastroesofágico capaz de alterar a qualidade de vida e a produtividade no trabalho dos doentes por ela acometidos. Instrumentos para esse tipo de avaliação são provenientes, em sua maioria, de países de língua inglesa e/ou francesa. A utilização desses instrumentos em nosso meio demanda criterioso processo de tradução e validação. OBJETIVOS: Traduzir para língua portuguesa os questionários GERD-HRQL (Gastroesophageal Reflux Disease - Health Related Quality of Life), HBQOL (Heartburn Specific Quality of Life Instrument) e GSAS (Gastroesophageal Reflux Disease Symptom Assessment Scale) específicos para avaliação de qualidade de vida na doença do refluxo gastroesofágico. Testar suas propriedades psicométricas de confiabilidade e validade. MÉTODOS: Cento e trinta e dois pacientes com doença do refluxo gastroesofágico (idade média 54,9 anos, ± DP 13,9) atendidos no ambulatório de motilidade digestiva da Universidade Federal de São Paulo, SP, e de gastrocirurgia da Faculdade de Medicina de São José do Rio Preto, SP, aceitaram participar do presente estudo, fornecendo termo de consentimento pós-esclarecimento. Destes, 40 pacientes participaram da fase de pré-teste (28 do sexo feminino e 12 do sexo masculino, com idade média de 55,3 anos, ± DP 14,7) e 92 da fase de validação (64 do sexo feminino e 28 sexo masculino, com idade média 54,7 anos e ± DP 13,7). A tradução e adaptação cultural foi realizada de acordo com o método de GUILLEMIN et al., sendo a validação dos questionários traduzidos (GERD-HRQL, HBQOL e GSAS) realizada em relação aos instrumentos genérico SF-36 e sintomático ESDRGE (SQGERD). RESULTADOS: A adaptação cultural implicou na troca de quatro palavras no GERD-HRQL, seis no HBQOL e nove no GSAS. Posteriormente a esta fase, o questionário GSAS foi abandonado por problemas no cálculo do escore, sendo as propriedades de medidas testadas nos dois questionários remanescentes, esses se mostraram reprodutíveis para uso inter e intra-observador com valores de 0,980 e 0,968, respectivamente, para o GERD-HRQL, e valores que variaram de 0,868 a 0,972, respectivamente, para o HBQOL. O questionário HBQOL demonstrou alta consistência interna (>0,70) para três das quatro dimensões avaliadas (aspecto físico, dor, sono). Os resultados encontrados na fase de validação apresentaram bons níveis de correlação com os questionários SF-36 e ESDRGE (SQGERD). CONCLUSÕES: As versões para a língua portuguesa (Brasil) dos instrumentos GERD-HRQL e HBQOL, adaptadas ao padrão cultural brasileiro, configuram-se em opções válidas, confiáveis, com baixo nível de desgaste do paciente e de fácil aplicação para avaliação de qualidade de vida na DRGE em nosso meio. O instrumento HBQOL é a única opção de avaliação multidimensional de qualidade de vida atualmente disponível para uso no Brasil. A versão em português do instrumento GSAS mostrou-se inadequada para avaliação de qualidade de vida na DRGE em nosso meio.


Author(s):  
Davide Bona ◽  
Greta Saino ◽  
Emanuele Mini ◽  
Francesca Lombardo ◽  
Valerio Panizzo ◽  
...  

Abstract Background The magnetic sphincter augmentation (MSA) device has become a common option for the treatment of gastroesophageal reflux disease (GERD). Knowledge of MSA-related complications, indications for removal, and techniques are puzzled. With this study, we aimed to evaluate indications, techniques for removal, surgical approach, and outcomes with MSA removal. Methods This is an observational singe-center study. Patients were followed up regularly with endoscopy, pH monitoring, and assessed for specific gastroesophageal reflux disease health-related quality of life (GERD-HRQL) and generic short-form 36 (SF-36) quality of life. Results Five patients underwent MSA explant. Four patients were males and the median age was 47 years (range 44–55). Heartburn, epigastric/chest pain, and dysphagia were commonly reported. The median implant duration was 46 months (range 31–72). A laparoscopic approach was adopted in all patients. Intraoperative findings included normal anatomy (40%), herniation in the mediastinum (40%), and erosion (20%). The most common anti-reflux procedures were Dor (n = 2), Toupet (n = 2), and anterior partial fundoplication (n = 1). The median operative time was 145 min (range 60–185), and the median hospital length of stay was 4 days (range 3–6). The median postoperative follow-up was 41 months (range 12–51). At the last follow-up, 80% of patients were off PPI; the GERD-HRQL and SF-36 questionnaire were improved with DeMeester score and esophageal acid exposure normalization. Conclusion The MSA device can be safely explanted through a single-stage laparoscopic procedure. Tailoring a fundoplication, according to preoperative patient symptoms and intraoperative findings, seems feasible and safe with a promising trend toward improved symptoms and quality of life.


2019 ◽  
pp. 55-59 ◽  
Author(s):  
O. A. Denisova ◽  
M. A. Livzan ◽  
A. P. Denisov ◽  
O. A. Kuhn

The demand of work is connected with prevalence a gastroesophageal reflux disease (GERB) against the background of insufficient study of age features of a course of this disease in the senior age groups. The research cohort made 96 patients with GERB. All patients were divided by method of randomization into two equal groups by quantity: the first – the persons receiving пантопразол 40 mg/days, the second – омепразол in a dose of 20 mg/days. Comparative study of efficiency of reception of an omeprazol and pantoprazol in age aspect at patients with GERB from positions of assessment of indicators of the quality of life (QL) was carried out. Indicators of KZh estimated on a visual and analog scale and the questionnaire of SF-36. Direct correlation connection between the level of health of patients and the following factors is established: existence of heartburn, the general time рН <4.0, number of refluxes in a minute, duration of the most long reflux in minutes. It was reasoned it is shown that at persons of the senior age groups in treatment of GERB пантопразол is more effective medicine, than омепразол. Patients of young and average age of the convincing proof have advantages of a pantoprazol before omeprazoly is not found. The result of the carried-out therapy in many respects is defined by degree of commitment of the patient. Therefore the choice of optimum approach to purpose of concrete medicine has to be carried out taking into account assessment of its safety, availability and the acceptability from the point of view of the patient.


Sign in / Sign up

Export Citation Format

Share Document